|
10068
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2007
|
Australia
|
6 months - 35 months
|
NA
|
Intramuscular
|
NA
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10069
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2007
|
Australia
|
3 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10070
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
6 months - 64 years
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10071
|
Fluarix Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
6 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10072
|
FluLaval Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
7 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10073
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
8 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10074
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
9 months and above
|
NA
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10075
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
10 months and above
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10076
|
Flucelvax Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
4 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Cell culture based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10077
|
Flucelvax Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
4 years and above
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
Hemagglutinin
|
Cell culture based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10078
|
Fluzone High-Dose Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10079
|
Fluad Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
MF59
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10080
|
Fluad Trivalent IIV (IIV3)
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
MF59
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10081
|
Flublok Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2013
|
NA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10082
|
FluMist Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
AstraZeneca plc
|
2003
|
Canada
|
2 - 49 years
|
Single dose
|
Intranasal
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
Tamiflu, Relenza
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10083
|
IL-YANG Quadrivalent Seasonal Influenza Vaccine
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Ilyang pharmaceutical Co. Ltd.
|
2020
|
South Korea
|
3 - 18 years
|
Single dose
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
NA
|
MFDS
|
NA
|
NA
|
NA
|
NA
|
NCT03445468
|
https://clinicaltrials.gov/ct2/show/NCT03445468?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=4
|
https://www.clincosm.com/trial/influenza-il-yang-quadrivalent-vaccine-flu-prefilled-syringe
|
|
10143
|
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
|
Influenza (flu)
|
Respiratory
|
Influenza A virus H5N1
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
ID Biomedical Corporation of Quebec
|
2013
|
USA
|
6 months and above
|
2 doses 21 days apart
|
Intramuscular
|
AS03
|
A/H5N1 influenza antigen
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/87479/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-h5n1-virus-monovalent-vaccine-adjuvanted
|
|
10144
|
AUDENZ
|
Influenza (flu)
|
Respiratory
|
Influenza A virus H5N1
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2020
|
USA
|
6 months and above
|
2 doses 21 days apart
|
Intramuscular
|
MF59
|
Influenza virus strain A/turkey/Turkey/1/2005-NIBRG-23
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/135020/download
|
https://www.fda.gov/vaccines-blood-biologics/audenz
|
|
10145
|
Fluvirin
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
USA
|
4 years and above
|
2 doses at least 1 month apart
|
Intramuscular
|
NA
|
Influenza subtypes A and B
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/75156/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/fluvirin
|
|
10356
|
V70P5
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Novartis
|
2015
|
USA
|
6 months - 71 months
|
2 doses
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
NA
|
NA
|
NA
|
NA
|
NBP607
|
NA
|
NCT00644059
|
https://clinicaltrials.gov/ct2/show/NCT00644059?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=14
|
NA
|
|
10357
|
NBP607-QIV
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
SK Chemicals Co. Ltd.
|
2015
|
South Korea
|
6 months - 18 years
|
1- 2 doses depending on volume and age
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
Cell culture based
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT02914275
|
https://clinicaltrials.gov/ct2/show/NCT02914275?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=18
|
NA
|
|
10358
|
Seqirus QIV
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Seqirus
|
2019
|
USA
|
6 months - 59 months
|
1- 2 doses depending on volume and age
|
Intramuscular
|
NA
|
Four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT02914275
|
https://www.clinicaltrials.gov/ct2/show/NCT02914275
|
NA
|